DavidJoshuaLedererMDMS

Pulmonology • Tarrytown, NY

Interstitial Lung Diseases, Pleural Disease

Medical Director, Clinical Development, Respiratory and Inflammation, Regeneron Pharmaceuticals, Inc.

Join to view full profile

Dr. Lederer is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lederer's full profile

Already have an account?

Office
775 Old Saw Mill River Rd
Tarrytown, NY 10591

Education & Training

Columbia University Mailman School of Public HealthM.S., Biostatistics, 2005 - 2007
New York Presbyterian Hospital (Columbia Campus)Fellowship, Pulmonary Disease and Critical Care Medicine, 2003 - 2006
New York Presbyterian Hospital (Columbia Campus)Chief Residency, Internal Medicine, 2002 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1999 - 2003
New York Presbyterian Hospital (Columbia Campus)Residency, Internal Medicine, 2000 - 2002
Columbia University Medical Center1999 - 2000
State University of New York Downstate Medical Center College of MedicineClass of 1999

Certifications & Licensure

NY State Medical License 2000 - 2025
American Board of Internal Medicine Critical Care Medicine
American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

Editorial Board American Journal of Respiratory and Critical Care Medicine, 2013
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Advisory Board POR Masters Degree Program, Irving Institute/Columbia CTSA, 2011
Chancellor’s Award State University of New York, 1999
Robert Wood Johnson Physician Faculty Scholar 2008-2011
Herbert and Florence Irving Scholar 2008-2011
Join now to see all

Clinical Trials

A Study of Aspirin and Simvastatin in Pulmonary Arterial Hypertension Start of enrollment: 2006 Sep 01
Terminated
Phase 2
Race, Ethnicity, and Diffuse Parenchymal Lung Disease Start of enrollment: 2006 Jul 01
Completed
Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
Terminated
Phase 2
Families-At-risk for Interstitial Lung Disease Study Start of enrollment: 2018 Jan 15
Completed
Assessment of Continuous Positive Airway Pressure Therapy in IPF Start of enrollment: 2023 Jan 01
Recruiting
Not Applicable
Join now to see all

Publications & Presentations

PubMed

2 citations
AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.
Klaus F Rabe, Fernando J Martinez, Surya P Bhatt, Tomotaka Kawayama, Borja G Cosio
ERJ Open Research. 2024-09-01
1 citations
Dupilumab sustains lung function improvements in patients with moderate-to-severe asthma.
Alberto Papi, Mario Castro, Jonathan Corren, Ian D Pavord, Yuji Tohda
Respiratory Medicine. 2024-04-01
9 citations
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study.
Leonard B Bacharier, Jorge F Maspero, Constance H Katelaris, Alessandro G Fiocchi, Remi Gagnon
The Lancet. Respiratory Medicine. 2024-01-01

Journal Articles

Reply
Dinesh Khanna, Elana J Bernstein, David J Lederer, Arthritis & Rheumatology
Bidirectional Transfer of Anelloviridae Lineages Between Graft and Host During Lung Transplantation
K M Olthoff, J D Christie, D J Lederer, R G Collman, J M Diamond, A Shaked, A R Haas, E Cantu, K Meyer, American journal of transplantation
Review: Update in surgical therapy for COPD.
Lederer DJ, Arcasoy SM, Clin Chest Med 2007; 28(3);639-53
Circulating KL-6, a Biomarker of Lung Injury, in Obstructive Sleep Apnea Disease. Poster Discussion.
Lederer DJ, Jelic S, Basner RC, Ishizaka A, Bhattacharya J., American Thoracic Society International Conference
Editorial: Socioeconomic barriers to lung transplantation: Balancing equity and access.
Hook JL, Lederer DJ, Am J Respir Crit Care Med
Letter: Is obstructive sleep apnea a cause of idiopathic pulmonary fibrosis?
Lederer DJ, Jelic S, Basner RC, Bhattacharya J, Arch Pathol Lab Med 2012;136(5):470
Editorial: Secondary prevention of IPF: Catching the horse still in the barn.
Lederer DJ, Am J Respir Crit Care Med 2012;185(7):697-9
Review: Selecting lung transplant candidates: where do current guidelines fall short?
Hook J, Lederer DJ, Expert Rev Respir Med 2012;6(1):51-61
Editorial: Translational research in lung transplantation: How do we get from mouse to human?
Lederer DJ, Am J Transplant 2012;12(2):281-2
Editorial: Two, one, or none for chronic obstructive pulmonary disease: Who decides and how?
Lederer DJ, Arcasoy SM, Am J Respir Crit Care Med 2011;184(11):1226-7
Review: Pulmonary hypertension in idiopathic pulmonary fibrosis.
Patel N, Lederer DJ, Borczuk A, Kawut SM, Chest 2007;132(3):998-1006
Lung volume reduction surgery for pulmonary emphysema: Improvement in the BODE index after 1 year.
Lederer DJ, Thomashow BM, Ginsburg ME, Austin JHM, Bartels MN, Yip CK, Jellen PA, Brogan FL, Kawut SM, Maxfield RA, DiMango AM, Simonelli PF, Gorenstein LA, Pearson GD..., J Thorac Cardiovasc Surg 2007;133(6): 1434-8
Successful bilateral sequential lung transplantation for pulmonary fibrosis associated with the Hermansky-Pudlak Syndrome.
Lederer DJ, Kawut SM, Sonett JR, Vakiani E, Seward SL Jr, White JG, Wilt JS, Marboe CC, Gahl WA, Arcasoy SM, J Heart Lung Transplant 2005;24:1697-9
Plasma monocyte chemotactic protein-1 levels at 24 hours are a biomarker of primary graft dysfunction after lung transplantation.
Shah RJ, Diamond JM, Lederer DJ, Arcasoy SM, Cantu EM, Demissie EJ, Kawut SM, Kohl B, Lee JC, Sonett J, Christie JD, Ware LB, Transl Res
Pulmonary arteriole gene expression signature in idiopathic pulmonary fibrosis.
Patel NM, Kawut SM, Arcasoy SM, Jelic S, Lederer DJ, Borczuk AC, Eur Respir J
The renin-angiotensin system and right ventricular structure and function: The MESA-Right Ventricle Study.
Ventetuolo CE, Lima JAC, Barr RG, Bristow MR, Bagiella E, Chahal H, Kizer JR, Lederer DJ, Bluemke DA, Kawut SM, Pulm Circ
Variation in PTX3 is associated with primary graft dysfunction after lung transplantation.
Diamond JM, Meyer NJ, Feng R, Rushefski M, Lederer DJ, Kawut SM, Lee JC, Cantu E, Shah R, Lama VN, Bhorade S, Crespo M, Demissie E, Sonett J, Wille K, Orens J, Weinack..., Am J Respir Crit Care Med 2012;86(6):546-552
A panel of lung injury biomarkers enhances the definition of primary graft dysfunction (PGD) after lung transplantation.
Shah RJ, Bellamy SL, Localio AR, Wickersham N, Diamond JM, Weinacker A, Lama VN, Bhorade S, Belperio JA, Crespo M, Demissie EJ, Kawut SM, Wille KM, Lederer DJ, Lee JC,..., J Heart Lung Transplant 2012;31(9):942-9
Plasma endothelin-1 and vascular endothelial growth factor levels and their relationship to hemodynamics in idiopathic pulmonary fibrosis.
Ventetuolo C, Kawut SM, Lederer DJ, Respiration 2012;84(4):299-305
Postoperative Estradiol Levels Associate With Development of Primary Graft Dysfunction in Lung Transplantation Patients.
Bastarache JA, Diamond JM, Kawut SM, Lederer DJ, Ware LB, Christie JD, Gend Med 2012;9(3):154-65
For the Lung Transplant Outcomes Group: Plasma levels of receptor for advanced glycation end-products (sRAGE), blood transfusion, and risk of primary graft dysfunction.
Christie JD, Shah CV, Kawut SM, Mangalmurti N, Lederer DJ, Sonett JR, Ahya VN, Palmer SM, Wille K, Lama V, Shah PD, Shah A, Weinacker A, Deutschman CS, Kohl BA, Demiss..., Am J Respir Crit Care Med 2009;180(10):1010-5
Join now to see all

Abstracts/Posters

Validation of the MDRD formula in estimating GFR in lung transplant candidates.
Al-Naamani N, Maarouf OH, Ahya VN, Lederer DJ, Mendez JD, Wilt JS, Rybak D, Tufariello M, D'Ovidio F, Sonett JR, Arcasoy S, Nickolas TL, Kawut SM, ISHLT Annual Meeting
Poverty predicts outcome in pulmonary arterial hypertension.
Okun J, Lederer DJ, Kawut SM, American Thoracic Society, San Francisco
Socioeconomic Status and Disease Severity in Diffuse Parenchymal Lung Disease.
Park S, Kawut SM, Simonelli PF, Patel NM, Al-Naamani N, Rybak D, Schluger NW, Arcasoy SM, Lederer DJ, ATS, Toronto
Predictors of Subclinical Restriction on Spirometry: The MESA Lung Study.
Lederer DJ, Enright PL, Kawut, SM, Hoffman EA, Hunninghake GW, Jiang R, Barr RG, ATS, Toronto
A Modified BODE Index Predicts Waiting List Survival in COPD.
Lederer DJ, Kawut SM, Wilt JS, D’Ovidio F, Sonett JR, Arcasoy SM, ATS, Toronto
Racial Differences in Waiting List Outcomes in Chronic Obstructive Pulmonary Disease.
Lederer DJ, Benn EKT, Barr RG, Wilt JS, Reilly G, Sonett JR, Arcasoy SM, Kawut SM, ATS, Toronto
Early Lung Transplant Outcomes in the New Allocation System: A Multicenter Study.
Shah RJ, Lederer DJ, Kawut SM, Ware LB, Christie JD, Arcasoy SM, ATS, Toronto
Histological Alveolar Injury Pattern Predicts Survival after Lung Transplantation.
Abrams DC, Lederer DJ, Kawut SM, Wilt JS, D’Ovidio F, Sonett JR, Marboe CC, Arcasoy SM, ATS, Toronto
Gene Expression Profiling of Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis.
Patel NM, Kawut, SM, Powell CA, Lederer DJ, Factor PH, Borczuk AC, ATS, Toronto
The MDRD formula predicts kidney failure after lung transplantation.
Al-Naamani N, Maarouf OH, Wilt JS, D'Ovidio F, Sonett JR, Arcasoy S, Nickolas TL, Lederer DJ, Kawut SM, ISHLT Annual Meeting
Predictors of gas exchange abnormality in emphysema.
Weingarten JA, Lederer DJ, Milite FM, Basner RC, American Thoracic Society, San Francisco, CA
The effect of CMV-immune globulin on outcomes in CMV-mismatched lung transplant recipients.
Tavares de Melo R, Lukose T, Bae S, Kubin C, Lederer D, Arcasoy S, Wilt J, Sonett J, D’Ovidio F, Kawut S, ISHLT poster presentation
Pretransplant Body Mass Index is Associated with Late Mortality after Lung Transplantation.
Lederer DJ, Wilt J, D'Ovidio F, Bacchetta M, Sonett JR, Arcasoy SM, American Thoracic Society International Conference
Criterion Validity of the Duke Activity Status Index in Diffuse Parenchymal Lung Disease.
Latreille M, Zemmel D, Philip N, Rybak D, Wilt J, Patel N, Kawut SM, Arcasoy SM, Lederer DJ, American Thoracic Society International Conference
Subclinical Parenchymal Lung Disease and Atherosclerosis in the MESA Lung Study.
Lederer DJ, Kawut SM, Johnson C, Enright P, Hunninghake GW, Raghu G, Hoffman EA, Carr JJ, Ahmed FS, Jacobs D, Watson K, Barr EG, American Thoracic Society International Conference, New Orleans, LA
Low Socioeconomic Status is Associated with Greater Disease Severity in IPF.
Giunta A, Arcasoy SM, Patel N, Wilt J, Lederer DJ, American Thoracic Society International Conference, New Orleans, LA
Elevated plasma TGF-beta1 levels are association with poor outcomes in IPF.
Poor H, Arcasoy SM, Kawut SM, Philip N, Rybak D, Huang M, Patel N, Shah L, Wilt J, Lederer DJ, American Thoracic Society International Conference, New Orleans, LA
Serum CA 15-3, a MUC1 tumor marker, is elevated in IPF.
Winterbottom C, Arcasoy SM, Philip N, Rybak D, Shimbo D, Patel N, Shah L, Wilt J, Lederer DJ, American Thoracic Society International Conference, New Orleans, LA
A Novel point-of-care oxygen titration study to predict outcome in ILD.
Hook J, Zemmel D, Philip N, Rybak D, Koeckert M, Shah L, Bartels M, Patel N, Arcasoy SM, Lederer DJ, American Thoracic Society International Conference, New Orleans, LA
Gas Exchange and Outcome Prediction in Idiopathic Pulmonary Fibrosis.
Hook J, Arcasoy SM, Zemmel D, Bartels M, Kawut SM, Lederer DJ, American Thoracic Society International Conference
A randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT.
Kawut SM, Bagiella E, Lederer D, Shimbo D, Horn EM, Roberts KE, Barr RG, Rosenzweig E, Post W, Palevsky HI, Tracy R, Hassoun PM, Girgis RE, American Thoracic Society International Conference
Racial and ethnic disparities in survival among patients with diffuse parenchymal lung disease.
Lederer DJ, Arcasoy SM, Kawut SM, et al, American Thoracic Society, San Diego, California
Six minute walk distance predicts waiting list survival in idiopathic pulmonary fibrosis.
Lederer DJ, Arcasoy SM, Barr RG, et al, Mini-oral presentation, ISHLT, Madrid, Spain
Obesity is Associated with an Increased risk of Primary Graft Dysfunction after Lung Transplantation.
Winterbottom C, Kawut SM, Ware LB, Bhorade S, Palmer SM, Wille KM, Weinacker A, Lama VN, Crespo M, Orens JB, Arcasoy SM, Christie JD, Lederer, DJ, American Thoracic Society International Conference, New Orleans, Louisiana
Temporal Trends in the Prevalence of Primary Graft Dysfunction after Lung Transplantation in the Lung Transplant Outcomes Group (LTOG) Cohort.
Robbins HY, Arcasoy SM, Bhorade S, Crespo M, Kawut SM, Lama VN, Orens JB, Palmer SM, Shah PD, Shah R, Sonett JR, Ware LB, Weinacker A, Wille KM, Christie JD, Lederer DJ, International Society for Heart and Lung Transplantation, San Diego, California
Join now to see all

Lectures

Evolving Concepts in Lung Transplantation.
American Thoracic Society International Meeting, Denver, Colorado
Obesity: How Heavy is too Heavy for Transplant?
American Thoracic Society International Conference, San Francisco, California
Pushing the Envelope: Reevaluating the Criteria for Lung Transplant Candidate Selection.
American Thoracic Society International Conference, San Francisco, California
Advances in Lung Transplantation” Lecture: Have the Transplant Criteria Changed Forever, and Not for the Better?
American Thoracic Society International Conference, San Francisco, California
How To Incorporate Measures Of Frailty In Assessment For Cardiothoracic Surgery.
International Society of Heart and Lung Transplantation Annual Conference, Prague, Czech Republic
The Aging Imperative: Ethics, Economics And Resource Allocation.
International Society of Heart and Lung Transplantation Annual Conference, Prague, Czech Republic
Geographic Disparities in Access to Lung Transplantation in the United States.
International Society of Heart and Lung Transplantation Annual Conference, Prague, Czech Republic
Lessons from Lung Transplant Database Analysis.
International Society of Heart and Lung Transplantation Annual Conference, Prague, Czech Republic
Lung Transplant Recipients: ISHLT Guidelines and the Impact of the LAS System.
American Thoracic Society International Meeting, Denver, Colorado
Disparities in Solid Organ Transplantation for Ethnic Minoritie.
Facts and Solutions Symposium, American Society of Transplantation Symposium, Washington, DC
The Need for Innovative Therapies for Advanced Lung Diseases.
American Thoracic Society International Meeting, Denver, Colorado
Stem Cells and Regenerative Medicine in Lung Disease and Transplantation.
American Thoracic Society International Meeting, Denver, Colorado
Plasma Leptin Levels are Associated with a Higher Risk of Primary Graft Dysfunction after Lung Transplantation.
International Society for Heart and Lung Transplantation, San Diego, California
Single versus Bilateral Lung Transplantation for Idiopathic Pulmonary Fibrosis: A Balanced Review of the Pros and Cons of Each Procedure.
International Society for Heart and Lung Transplantation, San Diego, California
Optimizing Lung Allocation: Square Pegs in Round Holes?
International Society for Heart and Lung Transplantation, San Diego, California
Improving Long Term Outcomes after Lung Transplantation: Insights from Clinical, Translational and Basic Research.
American Thoracic Society International Meeting, San Diego, California
and Ethnic Disparities in Waiting List Outcomes.
American College of Chest Physicians, Philadelphia, Pennsylvania
Join now to see all

Press Mentions

Liesbeth Stoeffler, 61, Runner Kept Going by Rare Lung Treatment, DiesMarch 26th, 2021
Puerto Rican Children and Girls Appear Less Likely to Use Their Asthma Inhalers Than Mexican American Children and BoysFebruary 5th, 2019
ATS Panel: U.S. Home Oxygen Delivery System BrokenDecember 13th, 2018
Join now to see all

Grant Support

Obesity, Inflammation, and Lung Injury after Lung TransplantationNational Heart Lung and Blood Institute2013–Present
Subclinical Interstitial Lung Disease In MESANational Heart, Lung, And Blood Institute2011–2012
Explaining Racial And Ethnic Disparities In Idiopathic Pulmonary FibrosisNational Heart, Lung, And Blood Institute2008–2011

Committees

Member, American Thoracic Society Document Development & Implementation Committee 2013 - Present
Member, ISHLT Lung Transplant Selection Guidelines Working Group
Member, Doctoral Admissions Committee, Mailman School of Public Health, Columbia Unviersity

Professional Memberships

American Thoracic Society - ATS
Member
American College of Chest Physicians - ACCP
Fellow
International Society for Heart and Lung Transplantation
Member

Industry Relationships

Consultant/Advisory Board, Gilead

External Links

Columbia Universityhttp://www.cumc.columbia.edu/pulmonary/faculty-and-staff/david-lederer-md-ms
David J. Lederer, MD, MShttp://www.cumc.columbia.edu/pulmonary/faculty-and-staff/david-lederer-md-ms
Patient Educationhttp://www.pfdoc.org